Share

EORTC proudly joins Walgreens Boots Alliance in a Transatlantic Charitable Partnership that aims to meet the needs of people living with cancer

Brussels, May 13, 2019 – The European Organisation for Research and Treatment of Cancer (EORTC), is one of the four organizations part of Walgreens Boots Alliance’s, Inc. (Nasdaq: WBA) Collaboration for Cancer Prevention, Research and Support, a transatlantic charitable partnership announced today. The partnership is between WBA and the EORTC, Macmillan Cancer Support and Susan G. Komen® with the aim to support people living with cancer at all moments of their journey.

The four organizations agreed to collaborate on initiatives to develop and support innovative cancer research infrastructure and to share best practices to improve patient care. WBA is committed to facilitating these collaborative efforts, supporting their success through fundraising and driving their impact through its pharmacy locations, a common touchpoint for people with cancer.

Ornella Barra, WBA Co-Chief Operation Officer and the Chairman of the company’s Corporate Social Responsibility Committee, said: “As a global health and wellbeing enterprise, WBA’s purpose is to help people live healthier and happier lives, and we are committed to doing all we can to support the fight against cancer. With our global health reach and broad network of partners, we are uniquely positioned to act as convener as we bring the best minds and organizations together to fight the disease. With cancer being a leading cause of death worldwide, WBA is accelerating and facilitating support for research and prevention, as well as assistance for people living with cancer, their loved ones and caregivers.

EORTC’s Director General Dr. Denis Lacombe noted, “EORTC has long recognized that if we are to advance treatment and quality of life for cancer patients across tumor types and across countries, we need to collectively work with like-minded organizations to deliver results for our patients. Today’s announcement marks the first steps towards a holistic and dynamic approach in the fight against cancer. With decades of expertise in clinical research and strong track records in changing practice trials, EORTC is proud to share its knowledge and contribute to this partnership as the unique pan-European cancer clinical research organization working across tumors and disciplines.”

For more information please visit Walgreens Boots Alliance.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023